In May 2016, XenoPort, Inc. was acquired by the privately held Arbor Pharmaceuticals LLC. and stopped trading. Xenoport Inc (NASDAQ:XNPT) is a biopharmaceutical company focused on harnessing the body's intrinsic cellular transport systems to improve the oral absorption, distribution and pharmacokinetics of drugs. The firm is focused on developing and commercializing a portfolio of internally discovered product candidates. In April 2011, the FDA approved first product, Horizant (gabapentin enacarbil) Extended-Release Tablets. In collbaoration iwth GlaxoSmithKline (GSK), intend to co-promote Horizant in the United States. The firm is also developing gabapentin enacarbil with Astellas Pharma Inc. in Japan and five Asian countries. XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including neuropathic pain, spasticity and Parkinson’s disease. Product candidates were discovered and developed by XenoPort utilizing our patented Transported Prodrug™ technology that utilizes the body's natural nutrient transport mechanisms. The firm has recieved multiple Michael J. Fox Foundation research grants for their work with Parkinsan's disease.
